Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.40 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898287 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3GSTO1CTSS | |
| SCHEMBL219603 | 0.80 | SMN1; SMN2 (0.49) | GSTO1F2 | |
| SCHEMBL895556 | 0.78 | MLYCD (0.39) | — | |
| SCHEMBL21422867 | 0.77 | PAX8 (0.44) | CHRM2CHRM1CHRM3CTSSCTSK | |
| SCHEMBL2929114 | 0.77 | MLYCD (0.38) | CTSSCTSK | |
| SCHEMBL11648528 | 0.77 | MLYCD (0.38) | — | |
| SCHEMBL3349318 | 0.77 | MLYCD (0.41) | — | |
| SCHEMBL3375082 | 0.77 | MLYCD (0.38) | — | |
| SCHEMBL266144 | 0.77 | MT-CO2 (0.46) | — | |
| SCHEMBL7341628 | 0.76 | CHRM2 (0.34) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | claimed |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-02-03 | — | — | US | claimed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | claimed |
| EP-4440563-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-10-09 | — | — | EP | claimed |
| CN-118338897-A | Compositions and methods for providing health benefits in animals using amino acid blends | 雀巢产品有限公司 | 2024-07-12 | — | — | CN | claimed |
| US-11974975-B2 | Compositions and methods using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+ precursor | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-05-07 | — | — | US | claimed |
| US-20240100006-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-03-28 | — | — | US | claimed |
| US-20240091186-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2024-03-21 | — | — | US | claimed |
| EP-4262776-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | Société des Produits Nestlé S.A. (CH) | 2023-10-25 | — | — | EP | claimed |
| EP-4259120-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-10-18 | — | — | EP | claimed |
| US-20220000820-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-01-06 | — | — | US | claimed |
| WO-2021232041-A1 | N-ACETYLCYSTEINE AND GLYCINE FOR TREATMENT OF COVID-19 AND POST COVID-19 SYMPTOMS | BAYLOR COLLEGE OF MEDICINE (US) | 2021-11-18 | — | — | WO | claimed |
| US-20210244696-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | BAYLOR COLLEGE OF MEDICINE | 2021-08-12 | — | — | US | claimed |
| EP-3855943-A2 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | Société des Produits Nestlé S.A. (CH) | 2021-08-04 | — | — | EP | claimed |
| CN-112654264-A | Using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+Composition and method of precursors | 雀巢产品有限公司 | 2021-04-13 | — | — | CN | claimed |
| US-10952982-B2 | Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2021-03-23 | — | — | US | claimed |
| WO-2020064946-A2 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | Société des Produits Nestlé S.A. (CH) | 2020-04-02 | — | — | WO | claimed |
| US-20180161297-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | Société des Produits Nestlé S.A. (CH) | 2018-06-14 | — | — | US | claimed |
| EP-3302459-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | Baylor College of Medicine (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191468-A1 | BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS | BAYLOR COLLEGE OF MEDICINE (US) | 2016-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | LIPC, GGT1, TGM2 | CHRM2 2058/4885CHRM1 1857/4885CHRM3 2091/4885 |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | LIPC, GGT1, TGM2 | CHRM2 1877/4885CHRM1 1728/4885CHRM3 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.